Skip to main content

Cybin, Inc. (CYBN)

NYSEAMERICAN: CYBN · IEX Real-Time Price · USD
2.08 0.00 (0.00%)
Sep 22, 2021 11:24 AM EDT - Market open
Market Cap331.45M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out158.59M
EPS (ttm)-0.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume260,303
Open2.10
Previous Close0.00
Day's Range2.07 - 2.18
52-Week Range0.00 - 2.18
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About CYBN

Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB0...

IndustryBiotechnology
IPO DateSep 13, 2019
Employees38
Stock ExchangeNYSEAMERICAN
Ticker SymbolCYBN
Full Company Profile

Financial Performance

Financial numbers in millions CADFinancial Statements

News

Cybin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysda...

1 week ago - Business Wire

Buying Cybin Stock Right Now Could Be a Brilliant Move

You'll need to be prepared for a long holding period and a hearty helping of risk.

2 weeks ago - The Motley Fool

Cybin Announces Additional Adelia Milestone Achievements

TORONTO--(BUSINESS WIRE)--Cybin Announces Additional Adelia Milestone Achievements

3 weeks ago - Business Wire

This Psychedelics Stock Could Grow 300% In One Year

Cantor Fitzgerald initiated coverage of Cybin (NYSE:CYBN), a drug development company in the psychedelics sector. Analysts gave Cybin an overweight rating and a 12-month price target of $9.

3 weeks ago - Benzinga

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) Files Two International Patent Applications In Support Of The Company's Research ...

Cybin (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed two additional international patent applications; these applications open the possibili...

1 month ago - Benzinga

Cybin Files Two Additional International Patent Applications in Support of the Company's Research Phase Programs

TORONTO--(BUSINESS WIRE)--Cybin Files Two Additional International Patent Applications in Support of the Company's Research Phase Programs

1 month ago - Business Wire

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and Receives a Favorable Patent Claim Opinion

TORONTO--(BUSINESS WIRE)--Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and Receives a Favorable Patent Claim Opinion

1 month ago - Business Wire

Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders' Meeting and Adoption of Sharehold...

TORONTO--(BUSINESS WIRE)--Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders' Meeting and Adoption of Shareholder Rights Plan

1 month ago - Business Wire

Cybin Inc. Announces 2021 First Quarter Financial Results and Business Highlights

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, announces the unaudited financia...

1 month ago - Business Wire

Cybin Announces Additional Adelia Milestone Achievements

TORONTO--(BUSINESS WIRE)--Cybin Announces Additional Adelia Milestone Achievements

1 month ago - Business Wire

Cybin to Present at Canaccord Genuity's 41st Annual Growth Conference on August 10th

TORONTO--(BUSINESS WIRE)--Cybin to Present at Canaccord Genuity's 41st Annual Growth Conference on August 10th

1 month ago - Business Wire

Cybin Becomes First Psychedelics Company On The NYSE: CEO Explains Everything You Need To Know

Cybin (NYSE:CYBN), a biotech company in the psychedelics space, began listing its stock on the New York Stock Exchange on Thursday. The company is the first in the sector to enter the NYSE, following a ...

1 month ago - Benzinga

Cybin to Commence Trading on the NYSE American on August 5

TORONTO--(BUSINESS WIRE)--Cybin to Commence Trading on the NYSE American on August 5

1 month ago - Business Wire

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

TORONTO--(BUSINESS WIRE)--CYBIN ANNOUNCES CLOSING OF OVERNIGHT MARKETED PUBLIC OFFERING OF COMMON SHARES AND EXERCISE OF OVER-ALLOTMENT OPTION

1 month ago - Business Wire

Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

TORONTO--(BUSINESS WIRE)--Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

1 month ago - Business Wire

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

TORONTO--(BUSINESS WIRE)--CYBIN ANNOUNCES SIZE AND PRICING OF PREVIOUSLY ANNOUNCED OVERNIGHT MARKETED PUBLIC OFFERING OF COMMON SHARES

1 month ago - Business Wire

Cybin Announces Overnight Marketed Public Offering of Common Shares

TORONTO--(BUSINESS WIRE)--CYBIN ANNOUNCES OVERNIGHT MARKETED PUBLIC OFFERING OF COMMON SHARES

1 month ago - Business Wire

Cybin Lands Conditional Approval To Become The First Psychedelics Company on The NYSE

Cybin Inc. (NEO: CYBN) (OTCQB:CLXPF), a biotech company in the psychedelics space, announced on Thursday a conditional approval to list on the New York Stock Exchange. “A tier 1 listing in the U.S. can ...

1 month ago - Benzinga

Cybin Announces Conditional Listing Approval from NYSE American

TORONTO--(BUSINESS WIRE)--Cybin Announces Conditional Listing Approval from NYSE American

2 months ago - Business Wire

Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy

TORONTO--(BUSINESS WIRE)--Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy

2 months ago - Business Wire

Cybin to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th

TORONTO--(BUSINESS WIRE)--Cybin to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th

2 months ago - Business Wire

Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio

TORONTO--(BUSINESS WIRE)--Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio

2 months ago - Business Wire

Missed the Initial Cannabis Boom? Check Out Hot Psychedelic Stock Cybin

The psychedelic-drug market is still in its early stages. And Cybin stands out as an early leader.

2 months ago - The Motley Fool

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More

Institutional analysts are taking a liking to the industry of medicinal psychedelics. This week, investment bank Maxim Group initiated coverage of companies in the psychedelics space, giving a bullish B...

Other symbols:MNMDENVB
2 months ago - Benzinga

3 Top Psychedelic Stocks to Buy Now

These companies developing hallucinogens have more than meets the eye.

Other symbols:CMPSMNMD
2 months ago - The Motley Fool